Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].

This article discusses the physiological mechanisms of erection and the pathophysiological basis of erectile dysfunction. Parameters characterizing the features of the pharmacokinetics and pharmacodynamics of drugs from the group of phosphodiesterase type 5 inhibitors (PDE-5i) are presented. The clinical efficacy and possible adverse effects of the most significant PDE-5i are considered. These include sildenafil, tadalafil, vardenafil, udenafil, avanafil. There are also data on less known PDE-5i, which include lodenafil and mirodenafil.

Citation

Z R Shodmonova, R R Gafarov, S A Allazov, Sh I Giyasov. Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction]. Urologiia (Moscow, Russia : 1999). 2021 May(2):135-140

Mesh Tags

Substances

PMID: 33960173

search → result